Krystal Biotech doses First Patient with Inhaled KB707 in the P-I study for treating Locally Advanced or Metastatic Solid Tumors of the Lung
Shots:
- Krystal has begun first patient dosing of KYANITE-1 (P-I) study of Inhaled KB707 monotherapy in an open label trial to treat LA/M solid tumors of the lung.
- Krystal Biotech received two US FDA FTDs for KB707 program: intratumoral use for anti-PD-1 r/r melanoma in Jul 2023 and inhaled use for solid tumors with pulmonary metastases in Feb 2024
- Inhaled KB707 is a modified HSV-1 vector designed to enter into the lung and deliver genes encoding both human IL-12 and IL-2. Krystal Biotech is expecting readout data in later 2024
Ref: Krystal Biotech | Image: Krystal Biotech
Related News:- Krystal Biotech Reports EMA’s Validation of Vyjuvek for MAA to Treat Dystrophic Epidermolysis Bullosa (DEB)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
